Advertisement
News
Advertisement

BMS Issues Voluntary Nationwide Recall of COUMADIN® for Injection Due to Presence of Particulate Matter

Mon, 06/30/2014 - 1:40pm

Bristol-Myers Squibb Company is voluntarily recalling six lots of COUMADIN® FOR INJECTION, 5 mg single-use vials in the U.S. This recall is a precautionary measure based on the company’s investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples. Bristol-Myers Squibb believes the safety risk to patients is low, and is further mitigated by the product’s prescribing information advising that intravenous drug products be inspected visually prior to administration.

Injected particulate metallic and non-metallic cellulose material can cause serious and potentially fatal adverse reactions such as embolization. Allergic reactions to the foreign material could also occur. To date, there have been no product complaints or adverse events reported to Bristol-Myers Squibb related to this issue.

COUMADIN FOR INJECTION was discontinued in early April 2014. The oral formulation, Coumadin tablets, is not impacted by this recall.

COUMADIN FOR INJECTION is a prescription medicine used to treat blood clots and to lower the chance of blood clots forming in the body. COUMADIN FOR INJECTION is typically administered in a hospital setting by health care professionals to patients not able to receive the oral formulation.

COUMADIN FOR INJECTION 5 mg single-use vials is packaged in cartons of six vials. The affected COUMADIN FOR INJECTION includes the following six lots distributed to hospitals and pharmacies from November 2011 through January 2014:

Bristol-Myers Squibb has issued recall communications to health care professionals and other customers involved and is arranging for return of all recalled products. Anyone that has COUMADIN FOR INJECTION which is being recalled should stop use and distribution and contact Bristol-Myers Squibb’s recall vendor, GENCO, at 1-855-838-5784 to arrange for return of remaining stock.

Bristol-Myers Squibb has issued recall communications to health care professionals and other customers involved and is arranging for return of all recalled products. Anyone that has COUMADIN FOR INJECTION which is being recalled should stop use and distribution and contact Bristol-Myers Squibb’s recall vendor, GENCO, at 1-855-838-5784 to arrange for return of remaining stock.

 

Health care professionals and patients may call the following number for assistance if they have further questions about the recall:

- See more at: http://news.bms.com/press-release/bristol-myers-squibb-issues-voluntary-nationwide-recall-coumadin-warfarin-sodium-injec#sthash.tZrBcoI9.dpuf

 

Lot Number

Description

NDC

Expiration

00201125

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

SEP 2014

00201126

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

NOV 2014

00201127

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

DEC 2014

00201228

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

JUN 2015

00201229

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

JUL 2015

00201230

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

SEP 2015

 
- See more at: http://news.bms.com/press-release/bristol-myers-squibb-issues-voluntary-nationwide-recall-coumadin-warfarin-sodium-injec#sthash.tZrBcoI9.dpuf

Bristol-Myers Squibb Issues Voluntary Nationwide Recall of COUMADIN® (warfarin sodium) FOR INJECTION Due to Presence of Particulate Matter

Monday, June 30, 2014 1:18 pm EDT
 

(NEW YORK – June 30, 2014)  – Bristol-Myers Squibb Company (NYSE:BMY) is voluntarily recalling six lots of COUMADIN® FOR INJECTION, 5 mg single-use vials in the U.S. This recall is a precautionary measure based on the company’s investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples. Bristol-Myers Squibb believes the safety risk to patients is low, and is further mitigated by the product’s prescribing information advising that intravenous drug products be inspected visually prior to administration.

Injected particulate metallic and non-metallic cellulose material can cause serious and potentially fatal adverse reactions such as embolization. Allergic reactions to the foreign material could also occur. To date, there have been no product complaints or adverse events reported to Bristol-Myers Squibb related to this issue.

COUMADIN FOR INJECTION was discontinued in early April 2014. The oral formulation, Coumadin tablets, is not impacted by this recall.

COUMADIN FOR INJECTION is a prescription medicine used to treat blood clots and to lower the chance of blood clots forming in the body. COUMADIN FOR INJECTION is typically administered in a hospital setting by health care professionals to patients not able to receive the oral formulation.

COUMADIN FOR INJECTION 5 mg single-use vials is packaged in cartons of six vials. The affected COUMADIN FOR INJECTION includes the following six lots distributed to hospitals and pharmacies from November 2011 through January 2014:

 

Lot Number

Description

NDC

Expiration

00201125

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

SEP 2014

00201126

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

NOV 2014

00201127

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

DEC 2014

00201228

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

JUN 2015

00201229

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

JUL 2015

00201230

COUMADIN LINJ 5MG (6VL) US

0590-0324-35

SEP 2015

 
 
 

Bristol-Myers Squibb has issued recall communications to health care professionals and other customers involved and is arranging for return of all recalled products. Anyone that has COUMADIN FOR INJECTION which is being recalled should stop use and distribution and contact Bristol-Myers Squibb’s recall vendor, GENCO, at 1-855-838-5784 to arrange for return of remaining stock.

 

Health care professionals and patients may call the following number for assistance if they have further questions about the recall:

 

General and Medical Inquiries:

 

Bristol-Myers Squibb Customer Information Center
1-800-332-2056

 

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

COUMADIN® (warfarin sodium) Prescribing Information (PDF: 172 KB)

- See more at: http://news.bms.com/press-release/bristol-myers-squibb-issues-voluntary-nationwide-recall-coumadin-warfarin-sodium-injec#sthash.tZrBcoI9.dpuf
Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading